Product Description
Mechanisms of Action: ADORA1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Biogen
Company Location: Eastern America
Company Founding Year: 1978
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Heart Failure|Kidney Diseases|Heart Failure, Acute|Acute Kidney Injury
Phase 2: Kidney Diseases|Heart Failure
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00858156 |
161HI101 | P1 |
Completed |
Healthy Volunteers |
2009-08-01 |
2019-03-18 |
Treatments |
|
NCT00745316 |
POSEIDON | P2 |
Terminated |
Kidney Diseases|Heart Failure |
2010-01-01 |
2019-03-18 |
Treatments |
|
2007-005721-30 |
POSEIDON | P2 |
Terminated |
Heart Failure|Kidney Diseases |
2009-12-14 |
2022-03-12 |
Treatments |
|
2007-007395-42 |
160HF301 , Trident I | P3 |
Completed |
Heart Failure, Acute|Acute Kidney Injury|Kidney Diseases |
2009-11-10 |
2022-03-12 |
Treatments |
|
NCT00709865 |
TRIDENT-1 | P3 |
Completed |
Kidney Diseases|Heart Failure |
2009-10-30 |
2023-09-12 |
||
ACTRN12608000607370 |
TRIDENT-1 , 160HF301 | P3 |
Terminated |
Heart Failure, Acute |
None |
2024-11-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|